Trial · NCT05770466
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients who are negative to SARS-CoV-2 at Day 8 | Up to Day 8 | Proportion of patients who are negative to SARS-CoV-2 based on quantitative (Ct value ≥30) RT-PCR at Day 8 or discharge before Day 8 due to recovery |
| Primary | Time to discharge from hospital | Up to Day 29 | Time to discharge from hospital according to the latest Taiwan CDC guidance for SARS-CoV-2 infection (From randomization to discharge) |
| Secondary | Proportion of patients who are negative to SARS-CoV-2 at Day 5 | Up to Day 5 | Proportion of patients who are negative to SARS-CoV-2 based on quantitative (Ct value ≥30) RT-PCR at Day 5 or discharge before Day 5 due to recovery |
| Secondary | Change in clinical status of patient at Day 5 | Up to Day 5 | Change in clinical status of patient on WHO clinical progression scale at Day 5 |
| Secondary | Change in clinical status of patient at Day 8 | Up to Day 8 | Change in clinical status of patient on WHO clinical progression scale at Day 8 |
| Secondary | Change of SpO2 | Up to Day 29 | Change of SpO2 from baseline |
| Secondary | Time from symptom onset to resolution of clinical signs and symptoms | Up to Day 29 | Time from the onset of clinical symptoms related to COVID-19 (e.g., fever, cough, dyspnea or change in taste or smell) to the resolution of clinical signs and symptoms. |
| Secondary | Time from symptom onset to RT-PCR negative result | Up to Day 29 | Time from the onset of clinical symptoms related to COVID-19 (e.g., fever, cough, dyspnea or change in taste or smell) to the RT-PCR negative result (Ct value ≥30). |
| Secondary | Time from RT-PCR positive result to the resolution of clinical signs and symptoms | Up to Day 29 | Time from RT-PCR positive result (Ct value \< 30) to the resolution of clinical signs and symptoms related to COVID-19 (e.g., fever, cough, dyspnea or change in taste or smell) |
| Secondary | Time from RT-PCR positive result to RT-PCR negative result | Up to Day 29 | Time from RT-PCR positive result (Ct value \< 30) to RT-PCR negative result (Ct value ≥30) |
| Secondary | Occurrence and duration (days) of supplemental oxygen | Up to Day 29 | Occurrence and duration (days) of supplemental oxygen |
| Secondary | Occurrence and duration (days) of mechanical ventilation | Up to Day 29 | Occurrence and duration (days) of mechanical ventilation |
| Secondary | Time to treatment with other antiviral agents within 8 days | Up to Day 8 | To evaluate the time to treatment with other antiviral agents within 8 days in the Ropeginterferon alfa-2b treatment group, |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05770466/registered